Launched in 2022 with $3 billion in funding, Altos Labs is dedicated to advancing regenerative technologies that have demonstrated benefits in animal models by extending both lifespan and healthspan.

At Altos, Mannick will focus on directing experimental science towards therapies aimed at combating age-related conditions, leveraging the company's expertise in cellular programming and computational modeling.

The company's mission is to reverse disease and age-related decline through partial epigenetic reprogramming, drawing inspiration from Nobel laureates Shinya Yamanaka and Juan Carlos Izpisua Belmonte.

To support its ambitious goals, Altos Labs operates research hubs in the San Francisco Bay Area, San Diego, and Cambridge, UK, attracting top scientific talent in the field.

Altos Labs has appointed Dr. Joan Mannick as Chief Medical Officer, signaling a potential shift towards clinical trials for its cellular rejuvenation programs.

While the company has not yet commenced human trials, Mannick's appointment suggests that Altos is preparing to enter this critical phase of development.

Mannick brings extensive experience in aging biology and drug development, having previously led clinical programs at various biotechnology firms, including Tornado Therapeutics and resTORbio.